Learning Objectives
At the end of this educational activity, participants should be able to:
- Recognize the latest systemic therapies for renal cell carcinoma
- Combine immune checkpoint inhibitors and targeted agents
- Identify and select patients who would benefit from these therapeutic approaches
- Monitor treatment response and mitigate adverse events